Bevacizumab
- Generic Name
- Bevacizumab
- Brand Names
- Avastin, Mvasi, Oyavas, Alymsys, Aybintio, Abevmy, Vegzelma, Onbevzi, Zirabev, Lytenava, Avzivi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 216974-75-3
- Unique Ingredient Identifier
- 2S9ZZM9Q9V
- Background
There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells. VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target for anti-cancer therapies.
...
- Indication
As a vascular endothelial growth factor (VEGF) inhibitor, bevacizumab is used in several chemotherapy regimens to treat metastatic colorectal cancer; metastatic, unresectable, locally advanced or recurrent non-squamous non-small cell lung cancer; metastatic renal cell carcinoma; metastatic, persistent, or recurrent cervical cancer; primary peritoneal cancer;...
- Associated Conditions
- Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Colorectal Cancer (CRC), Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Persistent Cervical Cancer, Recurrent Cervical Cancer, Recurrent Glioblastoma, Relapsed Glioblastoma, Stage III Fallopian Tube Cancer, Stage III Ovarian Epithelial Cancer, Stage III Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent Non-Squamous Non-Small Cell Lung Cancer, Recurrent Platinum-Sensitive Epithelial Ovarian Cancer, Recurrent Platinum-resistant Epithelial Ovarian Cancer, Recurrent platinum drug resistant Fallopian tube cancer, Recurrent platinum drug resistant primary peritoneal cancer, Recurrent platinum sensitive primary peritoneal cancer, Recurrent platinum-sensitive fallopian tube cancer, Unresectable Non-Squamous Non-Small Cell Lung Cancer, Unresectable, advanced Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
- Associated Therapies
- First Line Chemotherapy, First or Second Line Therapy, Second Line Treatment
Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-07-12
- Last Posted Date
- 2017-03-23
- Target Recruit Count
- 8
- Registration Number
- NCT00351039
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Clinical Study of Capecitabine, Oxaliplatin and Bevacizumab in Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-06-28
- Last Posted Date
- 2010-08-16
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 64
- Registration Number
- NCT00345761
- Locations
- 🇯🇵
Tokai Region, Tokai, Japan
🇯🇵Hokkaido Region, Hokkaido, Japan
🇯🇵Kanto Region, Kanto, Japan
1stline Study Capecitabine Administered on Continuous Way Plus Oxaliplatin&Bevacizumab Every 2weeks in Metastatic CCR.
- Conditions
- First Posted Date
- 2006-06-28
- Last Posted Date
- 2011-08-24
- Target Recruit Count
- 32
- Registration Number
- NCT00345696
- Locations
- 🇪🇸
Hospital 12 de Octubre, Madrid, Spain
A Study to Evaluate Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme (BRAIN)
- First Posted Date
- 2006-06-27
- Last Posted Date
- 2017-05-16
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 167
- Registration Number
- NCT00345163
Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers
- Conditions
- Interventions
- First Posted Date
- 2006-06-22
- Last Posted Date
- 2015-05-15
- Lead Sponsor
- Benaroya Research Institute
- Target Recruit Count
- 40
- Registration Number
- NCT00343044
- Locations
- 🇺🇸
Puget Sound Oncology Consortium (PSOC), Seattle, Washington, United States
🇺🇸Virginia Mason Medical Center, Seattle, Washington, United States
A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin)
- Conditions
- Interventions
- First Posted Date
- 2006-06-13
- Last Posted Date
- 2016-08-26
- Lead Sponsor
- Jaeb Center for Health Research
- Target Recruit Count
- 121
- Registration Number
- NCT00336323
- Locations
- 🇺🇸
Retina Consultants of Delmarva, P.A., Salisbury, Maryland, United States
🇺🇸Raj K. Maturi, M.D., P.C., Indianapolis, Indiana, United States
🇺🇸University of Washington Medical Center, Seattle, Washington, United States
Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2006-06-08
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 29
- Registration Number
- NCT00334815
- Locations
- 🇺🇸
Ballad Health Cancer Care - Norton, Norton, Virginia, United States
🇺🇸Providence Hospital, Mobile, Alabama, United States
🇺🇸Saint Bernards Regional Medical Center, Jonesboro, Arkansas, United States
A Study of Bevacizumab (Avastin) in Women With HER2 Negative Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-06-06
- Last Posted Date
- 2016-01-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 736
- Registration Number
- NCT00333775
Elaboration of a Model for Predicting Efficacy of Monoclonal Antibodies (Cetuximab and Bevacizumab) in Patients With Colorectal Cancer and Liver Metastases
- Conditions
- Interventions
- First Posted Date
- 2006-05-18
- Last Posted Date
- 2009-02-09
- Lead Sponsor
- Hospices Civils de Lyon
- Target Recruit Count
- 31
- Registration Number
- NCT00327093
- Locations
- 🇫🇷
Jean-Alain Chayvialle, Lyon, France
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery
- Conditions
- Interventions
- First Posted Date
- 2006-05-11
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1501
- Registration Number
- NCT00324805
- Locations
- 🇺🇸
Kaiser Permanente South Bay, Harbor City, California, United States
🇺🇸Kaiser Permanente Sacramento Medical Center, Sacramento, California, United States
🇺🇸OSF Saint Anthony's Health Center, Alton, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.